Homology Medicines appoints Brad Smith as CFO
Mr. Smith has more than 27 years of experience.
Prior to joining Homology Medicines, Mr. Smith served as CFO of Ocular Therapeutix, Inc., where he led the company's strategic financings, including an initial public offering and subsequent follow-on offerings, and completed a development and commercialization agreement with a major biopharmaceutical company.
Previously, Mr. Smith served as CFO of several other healthcare companies, including OmniGuide Surgical, NeuroMetrix, Inc., SYNARC, PatientKeeper, Inc. and Focal, Inc.
During his career, he has been instrumental in raising more than $450 million in private and public equity and debt financing, has played a key role in business development and strategic planning functions and has successfully guided three companies through the initial public offering process.
Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School at the University of New Hampshire, and he became a Certified Public Accountant while working at Coopers & Lybrand. ■
LATEST MOVES FROM Massachusetts
- PTC appoints Corinna Lathan to board
- J.Jill appoints James S. Scully to board
- Raytheon elects Robert O. Work as director
- Xenetic Biosciences appoints three directors
- Insulet appoints two to board
More inside POST